Metastasis is the leading cause of breast cancer-related death. Chemokine (C-C motif) receptor 7 (CCR7) plays important roles in breast cancer metastasis. However, the role of CCR7 in triplenegative breast cancer (TNBC) has not been fully elucidated. In this study, we found that CCR7 is highly expressed in both TNBC cell lines and breast cancer tissues. CCR7 was knocked down by shRNA in 4T1 and MDA-MB-231, two TNBC cell lines, and we found that the depletion of CCR7 significantly decreased TNBC cell proliferation, migration and invasion in vitro. Furthermore, we confirmed that the knockdown of CCR7 reduced the distant metastasis of 4T1 cells in an orthotopic mouse model. Proteomic analysis in 4T1 cells indicated that several signaling pathways such as epithelial cell adhesion molecule might contribute to CCR7's function in breast cancer metastasis. Our results suggest that CCR7 promotes TNBC metastasis and may serve as a target for breast cancer diagnosis and treatment.
Introduction
Breast cancer is one of the most lethal malignancies in women and causes more than 40,000 deaths every year in USA [1] . In recent years, the morbidity and fatality rates of breast cancer ranked the first and second places of female malignancies, respectively, in China [2] . Based on the expression status of the estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor 2 (HER2), breast cancer is classified into at least three subtypes: the luminal subtype (ERα and/or PR+), the HER2 subtype (HER2+), and triple-negative subtype (ERα-/ PR-/HER2-, triple-negative breast cancer [TNBC] ) [3] . TNBC is reported to be associated with higher metastasis and relapse frequencies, poorer prognosis and worse outcome compared with other subtypes because of lacking effective targeted therapies [4, 5] .
Breast cancer metastasis, particularly through lymph nodes, is the main cause of treatment failure in patients. It has been reported that axillary lymph node metastasis and the number of metastatic axillary lymph nodes are the most important prognostic factors for breast cancers [6, 7] . Generally, patients with more metastatic lymph nodes have higher metastatic axillary lymph node ratio and poorer prognosis [8] . Lymph node metastasis could be affected by various factors. Among them, chemokine (C-C motif) receptor 7 (CCR7) is an important marker for the prediction of axillary lymph node metastasis of breast carcinomas. It has been found that high CCR7 expression level is positively correlated with larger primary tumors, deeper lymphatic invasion and poorer survival rates [9, 10] .
CCR7 belongs to C-C chemokine receptors family, which is a GTP-protein-coupled 7-span transmembrane receptor and expressed on immune cells and endothelial cells membrane [11] . Through binding to its ligands, CCR7 could promote immune cell viability and induce immune cell homing to secondary lymphoid organs in immunologic and inflammatory processes [12] . CCR7 has two ligands, CCL19 (ELC) and CCL21 (SLC) [13] . Both CCR7 ligands are predominantly produced by stoma cells within primary and secondary lymphoid organs and are therefore considered to be homeostatic chemokines. CCL21 is also expressed by lymphatic endothelial cells in peripheral tissues [14] . Although most researches suggested that CCR7 is positively correlated with breast cancer metastasis, especially in lymph node metastasis, the role of CCR7 in breast cancer, especially TNBC, prognosis remains controversial [9, 15] .
In order to figure out how CCR7 regulates TNBC cell proliferation and metastasis, we silenced CCR7 in TNBC cell lines 4T1 and MDA-MB-231 and found that CCR7 knockdown inhibited 4T1 and MDA-MB-231 cell proliferation, migration and invasion in vitro and in vivo. In order to characterize how CCR7 regulates breast cancer metastasis, we performed proteomic analysis in CCR7-depleted and control 4T1 cells and found that several candidate proteins might mediate CCR7's function in breast cancer metastasis.
Materials and Methods

Cell lines and cell culture
All cell lines used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, USA). MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 (1:1) medium (Gibco, Grand Island, USA) supplemented with 10% fetal bovine serum. 4T1 and HEK-293T cells were cultured in DMEM medium supplemented with 5% fetal bovine serum (Hyclone, Logan, USA). All cells were maintained at 37°C with 5% CO 2 in a humidified atmosphere.
Transfection and CCR7-stable knockdown
All plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's protocols. The CCR7 short hairpin RNA (shCCR7) and control shRNA (shLacZ) were expressed using the pSIH1-H1-puro or pSIH1-H1-blasticidin lentiviral vectors. Target sequences of CCR7 shRNAs are listed in Supplementary data, Table S1 . MDA-MB-231 or 4T1 cells were infected with lentiviruses and selected using 2 μg/ml puromycin or 6 μg/ml blasticidin to generate stable cell populations.
Western blot analysis
Western blot analysis was performed as described previously [16] . Briefly, 30-40 μg of each protein sample was subjected to SDS-PAGE and blotted onto polyvinylidene fluoride membranes. After incubation with specific primary antibodies at 4°C overnight, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratory, West Grove, USA). The images were taken using an ImageQuant LAS4000 Biomolecular imager (GE, Bethesda, USA).The anti-CCR7 antibody was purchased from Abcam (Cambridge, UK). The anti-GAPDH antibody was purchased from Cell Signaling (Danvers, USA). The anti-β-actin antibody was purchased from Sigma (St Louis, USA).
Cell viability and proliferation assay
The cell viability was measured by sulforhodamine B (SRB) assays. Briefly, cells were seeded in 48-well plates at a density of 6 × 10 
Wound-healing assay
The wound-healing assay was performed in six-well plates. Briefly, 1.5 × 10 6 4T1 cells or 2 × 10 6 MDA-MB-231 cells were seeded in each well of six-well plates. Twenty-four hours after cell plating, wounds were made when the cells grow to 100% confluent using pipette tips, and the wound closure was recorded using a microscope every 4 h.
Matrigel invasion assay
The matrigel invasion assays were evaluated using chemotaxis matrigel chambers (BD BIOCOAT Matrigel chambers, 8-μm pore size) according to manufacturer's manuals. Briefly, 9 × 10 4 4T1 cells or MDA-MB-231 cells suspended in 100 μl serum-free medium were seeded in the insert, while 600 μl of culture medium supplemented with 10% FBS were added into the bottom chamber. The assembled chambers were then incubated at 37°C for 24 h. After incubation, cells that did not migrate to the underside of the insert were wiped off with cotton swabs, whereas the migrated cells were fixed with 4% paraformaldehyde, stained with crystal violet and washed with distilled water. Finally, three random fields were observed by microscopy, the crystal violet was dissolved with 33% acetic acid, and the absorbance was measured at a wavelength of 570 nm on a plate reader (Bio Tek).
4T1 tumor growth measurement
Female BABL/c mice were transplanted with 2.5 × 10 5 4T1 cells suspended in 50 μl PBS containing 40% matrigel into the fat pads at every injection point. Tumors were measured every week and the volume of the tumor mass was calculated according to the following formula: tumor volume (cm 3 ) = π (length × width 2 )/6. Mice were subjected to imaging on Days 8 and 41 after tumor implantation using the Xenogen IVIS-100 imaging system (Xenogen, Alameda, USA).
HE staining
All mice were sacrificed and organs (lung, spleen, liver and bone) were dissected for HE staining at the end of the experiment. Collected samples were fixed, trimmed, dehydrated and paraffinembedded, and sectioned. In brief, sections were deparaffinized in xylene, followed by rehydration in ethanol serials, and then stained in hematoxylin and eosin for 2 min respectively. After staining, sections were dehydrated in gradient ethanol, cleared by xylene and mounted with xylene-based mounting medium. Three random fields were observed by microscopy.
Proteomic analysis
The total proteins of CCR7 stably knockdown and control 4T1 cells were extracted and submitted for proteomic analysis in the Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China). Samples were analyzed using liquid chromatography tandem mass spectrometry (LC-MS-MS; Nano-ESI Velos Pro-Orbitrap Elite mass spectrometer; Thermo Electron, Waltham, USA) to identify the expression level of proteins. MaxQuant (http://maxquant.org/, version 1.3.0.5) was used to generate peak lists from raw files, and Andromeda was used to search the protein sequence database. The significantly changed proteins were imported to Ingenuity Pathways Analysis software (IPA, version 8.5; Ingenuity Systems, Redwood City, USA), and these proteins were classified by molecular function annotation [17] .
Statistical analysis
Data are shown as the mean ± SD. Student's t-test was used to compare two datasets. Fisher's exact test was used to compare two small datasets of categorical data. GraphPad Prism 6 and SPSS 17.0 Software were used for all statistical analyses. P-values <0.05 were considered significant.
Results
CCR7 is highly expressed in TNBC
It was reported that CCR7 is highly expressed in breast cancer tissues, especially in TNBC and luminal B-type breast cancer [15, 18, 19] . Therefore, we analyzed the gene expression data from TCGA database and found that the expression of CCR7 at mRNA level is relatively higher in triple-negative subtype breast cancers compared with that in normal breast tissues (Fig. 1A) . Since the expression of CCR7 in different breast cancer cell lines has not been detected, we collected proteins from 12 breast cell lines, including three immortalized breast cell lines (184A1, 184B5 and MCF-10A), four estrogen receptor-positive (ERα+) cell lines (HCC1500, MCF-7, T47D, MDA-MB-361) and five TNBC cell lines (MDA-MB-231, MDA-MB-468, HCC1806, HCC1937 and 4T1). As shown in Fig. 1B, CCR7 was not detected in three immortalized breast cell lines; however, CCR7 is highly expressed in six breast cancer cell lines, including four TNBC cell lines (MDA-MB-231, 4T1, HCC1937 and MDA-MB-468) and two ERα+ breast cancer cell lines (T47D and MCF-7). Since CCR7 is highly expressed in MDA-MB-231 and 4T1 cell lines, two TNBC cell lines with high mobility and widely used models in tumor metastasis studies [20] , we used these two cell lines in the subsequent experiments.
Knockdown of CCR7 inhibited TNBC cell proliferation
We first investigated the effect of CCR7 on TNBC cell growth. CCR7 was depleted in 4T1 and MDA-MB-231 cell lines ( Fig. 2A,C) and cell growth was examined using the SRB assay. As shown in Fig. 2B ,D, CCR7 depletion significantly decreased cell growth.
Knockdown of CCR7 inhibited TNBC cell migration and invasion in vitro
It is well known that CCR7 contributes to breast cancer cell mobility [9, 11, 21] , we examined whether CCR7 affects TNBC cell migration and invasion using wound-healing and transwell analyses. Indeed, CCR7 silencing significantly suppressed wound-healing ability of 4T1 cells (Fig. 3A) . Meanwhile, transwell invasion assays confirmed that CCR7 knockdown significantly decreased the invasion ability of 4T1 cancer cells (Fig. 3B) . Furthermore, the depletion of CCR7 suppressed the migration and invasion ability of human TNBC MDA-MB-231 cells ( Supplementary Fig. S1 ), which is consistent with previous studies [22] .
Knockdown of CCR7 inhibited 4T1 metastasis in vivo
It was reported that the expression of CXCR4 and CCR7 is positively associated with lymph node metastasis and the expression of these receptors can serve as indicators of undesirable prognosis in patients with breast cancer [9] . Whether CCR7 promotes breast tumor growth and metastasis has not been tested. We tested it using the stable CCR7-knockdown 4T1 cells and control cells. Stable CCR7-knockdown and control 4T1 cells were orthotopically injected into the fat pad of female BABL/c mice (2 × 10 5 cells/point).
Tumor metastasis was monitored via detecting bioluminescence activity at Days 8 and 41 after inoculation (Fig. 4A) because the 4T1 cells stably expressed luciferase. The tumor sizes were measured twice a week (Fig. 4B) . 4T1 tumor growth was significantly inhibited by CCR7 depletion. Moreover, most of the mice (8 out of 9) in the control group developed metastasis, whereas only 3 out of 9 mice in the CCR7 depletion group showed distant metastasis at Day 41 (Fig. 4C,D, and Table 1 ). Six weeks after tumor cell inoculation, tumor tissues and several main organs including the brain, liver, spleen, lung and bones were collected for HE staining. Metastases were identified in the spleen, lung, liver and sternum tissues. In consistent with luciferase reporter assays, metastases in the CCR7 depletion group were much less than those in the control group (Fig. 4D , and Table 1 ).
We also established another metastasis model in BABL/c mice by injecting 4T1 tumor cells (1 × 10 6 /mice) through tail veins; however, CCR7 knockdown did not affect distal metastasis ( Supplementary   Fig. S2 ). This result is consistent with previous studies showing that CCR7 is mainly involved in lymph nodes metastasis in breast cancer [10, 23, 24] . Taken together, our data suggest that CCR7 plays important roles in promoting TNBC cell growth, migration and metastasis.
Identification of proteins regulated by CCR7
It has been reported that CCR7 promotes breast tumorigenesis through promoting stemness [25] and inducing epithelial-mesenchymal transition [22, 26] . Several signaling pathways, including Notch1, PI3K/AKT, ERK and MAPK [27] [28] [29] [30] , have been suggested to be regulated by CCR7. However, the mechanisms by which CCR7 promotes TNBC metastasis have not been systematically clarified. To identify CCR7-regulated proteins in TNBC, we extracted total proteins from CCR7-knockdown and control 4T1 cells for proteomic analysis. Compared with the control cells, 376 proteins were found to be differentially expressed after CCR7 depletion (Fig. 5A) , the top 10 upregulated and downregulated proteins are listed in Supplementary Table S2 . Several metastasis-related genes, such as epithelial cell adhesion molecule (EpCAM), AnxA6, PVR and ALDH3A2 were also identified, indicating that CCR7 might regulate 4T1 cell metastasis through EpCAM and PVR downstream target proteins (Fig. 5B) . Whether CCR7 functions through these target proteins and how CCR7 regulates their expression need further investigation in the future.
Discussion
CCR7 is associated with metastasis in numerous malignancies, including melanoma, gastrointestinal carcinomas and breast cancer [23, [31] [32] [33] . Strien et al. [18] demonstrated that CCR7 is highly expressed in luminal B-type breast cancer tissues, as compared to luminal A type. Weitzenfeld et al. [28] indicated a significant correlation between high CCR7 levels and the elevated proportion of lymph node involved in luminal B patients but not in luminal A breast cancer patients, which implicated a positive correlation between CCR7 and lymph node metastasis. We previously found that the expression of CCR7 is higher in breast cancer tissues than in normal breast tissues [34] . Furthermore, the positive rate of CCR7 in TNBC is higher than that in non-TNBC samples [19] . Meanwhile, Li et al. [15] found that CCR7 was overexpressed in TNBC and positively correlated with lymph node metastasis. However, it still remains unclear whether CCR7 affects TNBC cell metastasis in animal models. In this study, we demonstrated that CCR7 depletion significantly suppressed TNBC cell growth, migration and invasion. For the first time, we confirmed that CCR7 promoted breast cancer cell metastasis using 4T1 cells in BABL/c mice. Furthermore, we first performed a high-throughput proteomic analysis in CCR7-depleted 4T1 cells and identified several metastasisrelated proteins regulated by CCR7. Xu et al. [22] recently reported that silencing CCR7 decreased CCL19-induced breast cancer cell proliferation, migration and invasion in MDA-MB-231 and MCF-7 in vitro. Li et al. [21] also reported that knockdown of CCR7 blocked CCL21-induced MDA-MB-231 cell migration and invasion in vitro. Consistent with these findings, we obtained similar results in both mouse and human TNBC cell lines (4T1 and MDA-MB-231) even without ligand stimulation. Furthermore, we also tried to overexpress CCR7 in MCF-7, an ERα+ cell line with relatively lower expression level of CCR7. We used several different eukaryotic gene expression vectors and even CCR7-expressing lentivirus, but unfortunately none of these systems worked. Therefore, we could not detect CCR7 overexpression at protein level. It was reported that the depletion of CCR7 reduced PyMT-induced mammary tumor formation [25] , and CCR7 overexpression dramatically increased lymph node metastasis when PyMT-induced breast cancer cells were orthotopically injected into the mammary fat pad of FVB mice [24] . Most importantly, we investigated the role of CCR7 in metastasis in BABL/c mice. We found that CCR7 depletion did not affect breast cancer cell metastasis when the 4T1 cells were injected via tail veins but suppressed metastasis when the cells were orthotopically injected. These results are consistent with previous findings that CCR7 did not affect liver and lung metastasis of TD-2 cells when the cells were injected via tail veins [35] but increased B16 cell metastasis to draining lymph nodes [36, 37] .
The mechanisms by which CCR7 promotes metastasis have not been fully elucidated. It was reported that CCR7 promoted cancer progression by regulating not only tumor microenvironment, such as T cell activation, immune tolerance and inflammatory response [38] but also cell mobility and anoikis of cancer cells [39] . Several signaling pathways, including NF-κB, PI3K/Akt/VEGF-C and TGF-β [26, 30, 40] have been reported to be regulated by CCR7 in different types of cancer cells. COX-2 and hypoxia have been reported to promote CCR7 expression, which contributes to cancer metastasis [41, 42] . However, how CCR7 contributes to TNBC cell mobility is still not fully understood. In this study, we identified several potential downstream proteins of CCR7, such as EpCAM [43, 44] , AnxA6 [45, 46] , PVR [47] [48] [49] and ALDH3A2 [50, 51] , which have been reported to be associated with metastasis. EpCAM, a protooncogene, was revealed to be associated with tumor progression and poor prognosis in breast cancer [44] . However, how these proteins are regulated by CCR7 still needs to be further investigated.
In summary, our results clearly suggest that the knockdown of CCR7 reduces TNBC cell proliferation, migration and invasion as well as metastasis.
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